Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy
Olaparib is recommended, within its marketing authorisation, as an option for treating HER2-negative locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults who ...
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy
The appraisal committee has prepared final draft guidance (FDG) on olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336] and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback